7-Hydroxymitragynine: What You Need to Know

This article is for informational purposes only and does not constitute medical advice. Consult a qualified healthcare provider before making health decisions based on this content.

By KratomCBDDirect.com Editorial Team | Last verified: August 2026

What 7-Hydroxymitragynine Is

7-hydroxymitragynine (7-OH-MIT, or simply “7-OH”) is an alkaloid—a naturally occurring plant chemical—found in small amounts in kratom leaf (Mitragyna speciosa). The compound is classified as a terpenoid indole alkaloid, a class of complex organic molecules with effects on the nervous system.

In natural kratom leaves, 7-OH-MIT typically comprises less than 2% of the alkaloid content. However, most commercial 7-OH products sold today are semisynthetic—meaning they are produced in laboratories through chemical oxidation of kratom alkaloid extracts, rather than extracted directly from the plant. This distinction matters: semisynthetic production can yield much higher concentrations than exist naturally, changing both potency and safety profile.

7-OH-MIT also forms naturally in your body when you consume kratom. Your liver (via the CYP450 enzyme system) metabolizes mitragynine into 7-OH-MIT and other compounds—so some amount of 7-OH exposure occurs with regular kratom use.

How 7-Hydroxymitragynine Works in Your Body

Opioid Receptor Binding

7-OH-MIT's primary mechanism involves binding to opioid receptors in your brain and nervous system. Specifically, it acts as a partial agonist at mu-opioid receptors (MOR)—meaning it binds and partially activates these receptors—while blocking (antagonizing) delta and kappa opioid receptors.

What makes 7-OH-MIT noteworthy is its binding affinity. Published studies report MOR binding affinity in the range of 13.5–37 nanoMolar (nM), compared to morphine at significantly lower affinity. In one electrical stimulation test, 7-OH-MIT showed opioid agonist potency approximately 13 times higher than morphine—a substantial difference.

The β-Arrestin Question

Unlike traditional opioids (morphine, oxycodone), 7-OH-MIT does not appear to recruit the β-arrestin signaling pathway. Researchers hypothesize this might reduce certain side effects (respiratory depression, constipation) associated with classical opioids. However, this remains theoretical; human safety data is limited, and animal studies still documented respiratory depression with 7-OH-MIT.

Tolerance and Withdrawal

Animal studies show that chronic 7-OH-MIT use produces cross-tolerance with morphine—meaning tolerance to one develops tolerance to the other. Similarly, withdrawal symptoms induced by naloxone (an opioid antagonist) appeared equally in animals repeatedly dosed with 7-OH-MIT or morphine, indicating genuine opioid-like withdrawal potential.

What the Research Shows About 7-Hydroxymitragynine

Animal Studies: Analgesia and Safety Signals

Most human-relevant research on 7-OH-MIT comes from animal (rodent and guinea-pig) studies:

• Analgesia: 7-OH-MIT produced dose-dependent pain relief in mice, consistent with opioid activity.
• Respiratory Depression: When given intravenously, both mitragynine and 7-OH-MIT caused respiratory depression in animal models—a serious concern shared with traditional opioids.
• Seizures: Seizures were observed in surviving mice given high doses of mitragynine; the seizure risk from 7-OH-MIT specifically is less clear.
• Lethal Dose: One study could not identify an oral lethal dose in mice (no deaths occurred at tested doses), but this does not establish human safety.

Evidence Grade: Preliminary. No published human randomized controlled trials of 7-OH-MIT for pain, anxiety, or any other condition exist. All mechanistic and safety data come from animal models.

Real-World Safety: Poison Control Data

The most concerning evidence is epidemiological. The U.S. Poison Control Center received:

• Fewer than 200 kratom-related reports in 2014
• Approximately 1,600 reports in 2024—a roughly 700% increase
• Approximately 40% of 7-OH-MIT reports involved intentional abuse or misuse

This trend suggests rising exposure and, by proxy, rising adverse events in the general population.

Forms and How 7-Hydroxymitragynine Enters Your Body

Commercial Products

7-OH-MIT is sold primarily as:

• Tablets / capsules: Semisynthetic 7-OH-MIT powder compressed into pills, often sold in gas stations and smoke shops without dosage standardization or warnings
• Extracts: Concentrated kratom extracts with elevated 7-OH-MIT levels
• “kratom extracts”: Marketed for rapid onset and potency

Bioavailability and Absorption

Limited data exists on 7-OH-MIT absorption rates in humans. Oral bioavailability (the percentage of a dose that reaches your bloodstream) is unknown. Animal studies used intravenous dosing (injection directly into veins) for precise measurement; real-world tablet/capsule use relies on oral absorption, which may be variable and affected by food, individual liver function, and formulation.

Safety, Side Effects, and Drug Interactions

Known and Reported Side Effects

Based on poison control reports and user accounts, 7-OH-MIT has been associated with:

• Dizziness, nausea, vomiting
• Sedation and drowsiness
• Respiratory depression (documented in animal studies; likely in humans at higher doses)
• Seizures (reported with kratom alkaloids; mechanism unclear)
• Psychological dependence and withdrawal symptoms (irritability, insomnia, muscle aches, anxiety)
• Overdose risk, particularly when combined with other depressants

Regulatory Status and Toxicity Concerns

In July 2025, the U.S. Food and Drug Administration formally recommended that the Drug Enforcement Administration (DEA) classify 7-OH-MIT as a Schedule I controlled substance. This action reflects:

• High abuse potential and dependency risk
• Lack of accepted medical use in the United States
• Escalating poison control reports and emergency department visits
• Animal evidence of respiratory depression and seizures

As of August 2026, Schedule I classification status may vary by jurisdiction; readers should verify local legal status before purchase or use.